Open figure viewer
Based on an investigation by the College of Medicine Investigation Committee (the COMIC) at The Ohio State University, and JEM’s review, JEM is issuing this Expression of Concern regarding Figures 1 E and 1 F from Pichiorri et al. (2013) J. Exp. Med. 210(5):951–68 and Correction Pichiorri et al. (2017) J. Exp. Med. 214(5):1557.
Vol. 210, No. 5 | https://doi.org/10.1084/jem.20120950 | April 22, 2013
Vol. 214, No. 5 | https://doi.org/10.1084/jem.2012095001172017c | January 19, 2017
Flavia
Pichiorri
, Dario
Palmieri
, Luciana
De Luca
, Jessica
Consiglio
, Jia
You
, Alberto
Rocci
, Tiffany
Talabere
, Claudia
Piovan
, Alessandro
Lagana
, Luciano
Cascione
, Jingwen
Guan
, Pierluigi
Gasparini
, Veronica
Balatti
, Gerard
Nuovo
, Vincenzo
Coppola
, Craig C.
Hofmeister
, Guido
Marcucci
, John C.
Byrd
, Stefano
Volinia
, Charles L.
Shapiro
, Michael A.
Freitas
, and Carlo M.
Croce
. 2013
. J. Exp. Med
. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
. 210
:951
–968
. https://doi.org/10.1084/jem.20120950Flavia
Pichiorri
, Dario
Palmieri
, Luciana
De Luca
, Jessica
Consiglio
, Jia
You
, Alberto
Rocci
, Tiffany
Talabere
, Claudia
Piovan
, Alessandro
Lagana
, Luciano
Cascione
, Jingwen
Guan
, Pierluigi
Gasparini
, Veronica
Balatti
, Gerard
Nuovo
, Vincenzo
Coppola
, Craig C.
Hofmeister
, Guido
Marcucci
, John C.
Byrd
, Stefano
Volinia
, Charles L.
Shapiro
, Michael A.
Freitas
, and Carlo M.
Croce
. 2017
. J. Exp. Med
. Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
. 214
:1557
. https://doi.org/10.1084/jem.2012095001172017c© 2022 Rockefeller University Press
2022
This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
